FDA strengthens methotrexate labelling: folic acid co-administration and hepatotoxicity monitoring
FDA required updated labelling for low-dose oral methotrexate (used in rheumatoid arthritis, psoriasis, and other inflammatory conditions) to reinforce the need for folic acid co-administration to reduce mucositis and hepatotoxicity risk, and to clarify liver biopsy monitoring thresholds. The update follows a post-market safety review of hepatotoxicity cases in patients on chronic low-dose regimens.
Methotrexate ↗ is a dihydrofolate reductase (DHFR) inhibitor used at low weekly doses (7.5–25 mg/week) for rheumatoid arthritis, psoriatic arthritis, psoriasis, and other inflammatory conditions. The updated FDA label strengthens three key requirements: (1) mandatory folic or folinic acid co-prescription to reduce folate-depletion toxicity; (2) clarified liver biopsy thresholds — recommending cumulative dose-based and risk-stratified monitoring; and (3) enhanced patient counselling on hepatotoxicity signs (jaundice, abdominal pain, dark urine).
Why folic acid matters with methotrexate
Methotrexate inhibits DHFR, blocking conversion of dihydrofolate to tetrahydrofolate — the active form needed for nucleotide synthesis and one-carbon transfer reactions. This mechanism causes both its anti-inflammatory benefit (via aminoimidazole carboxamide ribonucleotide [AICAR] accumulation and adenosine release) and its toxicity. Folic acid supplementation ↗ (typically 1–5 mg/day on non-MTX days) replenishes the folate pool, reducing mouth sores, nausea, and hepatocellular toxicity without significantly impairing the anti-inflammatory mechanism. See Dhir et al., Drugs 2014 ↗ for the systematic review.
Hepatotoxicity monitoring guidance
The updated label recommends baseline LFTs and albumin before starting methotrexate, with periodic monitoring every 4–8 weeks. Liver biopsy is now recommended only for patients with persistent LFT elevations (>3× ULN on three tests over 12 months) or cumulative dose ≥3.5–4 g in high-risk patients (pre-existing liver disease, alcohol use, obesity, diabetes). The ACR ↗ and BAD (UK) ↗ guidelines provide risk-stratified protocols. For full label text, see DailyMed methotrexate ↗.
Key drug interactions to review
NSAIDs reduce renal methotrexate clearance by competing for tubular secretion — a clinically significant interaction at both low and high doses. Renal transporters OAT1/OAT3 mediate active secretion of methotrexate; NSAID co-administration can increase MTX levels 2–3-fold. Trimethoprim-sulfamethoxazole (TMP-SMX) potentiates folate depletion and bone marrow suppression. Proton pump inhibitors can reduce renal MTX clearance. The FDA DDI table ↗ lists methotrexate as an OAT1/OAT3 substrate.
FAQ
Does a Boxed Warning mean a drug is being withdrawn?
No. A Boxed Warning ↗ (also called a Black Box Warning) is the FDA's strongest label caution, but the drug remains on the market. It means the agency has determined that a risk is serious enough to require prominent, standardised labelling. The drug continues to be prescribed under appropriate clinical conditions. See the FDA's patient guide to Boxed Warnings ↗.
Where can I read the full updated label?
All current FDA-approved prescribing information is available on DailyMed ↗, maintained by the National Library of Medicine (NLM). Search by drug name to find the most recent label version. Historical label versions are also archived there.